Sanofi’s Tolebrutinib Misses Two of Three Late-Stage Multiple Sclerosis Readouts

The BTK inhibitor showed promise in non-relapsing secondary progressive multiple sclerosis but not relapsing MS. The company said it plans to apply for approval for the former “as soon as possible.”